<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00136786</url>
  </required_header>
  <id_info>
    <org_study_id>#4725(A)</org_study_id>
    <secondary_id>R01DA017572</secondary_id>
    <secondary_id>DPMC</secondary_id>
    <nct_id>NCT00136786</nct_id>
  </id_info>
  <brief_title>Effect of Memantine Versus Bupropion on Smoking Relapse in Nicotine-Dependent Individuals - 3</brief_title>
  <official_title>Effect of Memantine Versus Bupropion on Smoking Relapse in Nicotine-Dependent Individuals</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New York State Psychiatric Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>New York State Psychiatric Institute</source>
  <brief_summary>
    <textblock>
      One of nicotine's effects on the body is at the level of the NMDA receptors in the brain.&#xD;
      Memantine is a drug that also affects NMDA receptors, making it a candidate for the treatment&#xD;
      of nicotine addiction. The purpose of this study is to evaluate the effectiveness of&#xD;
      memantine using a laboratory model of smoking relapse in nicotine dependent volunteers.&#xD;
      Investigators will compare the effects of memantine with bupropion, medication currently used&#xD;
      to facilitate smoking cessation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Tobacco use is the leading preventable cause of death in the United States. Recent research&#xD;
      on the effects of nicotine on the brain and behavior presents an opportunity to advance&#xD;
      medication development. Neurotransmission at NMDA receptors in the brain is associated with&#xD;
      learning and memory and has been linked to many of nicotine's effects on humans. It is&#xD;
      possible that altering NMDA neurotransmission may be helpful in treating nicotine addiction.&#xD;
      The goal of this study is to evaluate the effects of memantine, an NMDA receptor antagonist,&#xD;
      using the laboratory model of smoking relapse in nicotine dependent volunteers. The effects&#xD;
      of memantine used in combination with bupropion, a medication currently used to facilitate&#xD;
      smoking cessation, will be compared to a placebo.&#xD;
&#xD;
      This double-blind study will consist of three phases (placebo, bupropion, and memantine).&#xD;
      Each phase will include 10 days of outpatient medication maintenance, followed by 5 days of&#xD;
      inpatient testing. During the outpatient phase, study visits will occur every 2 to 3 days.&#xD;
      During the first portion of inpatient stay, participants will not be permitted to smoke.&#xD;
      During the second portion of inpatient stay, smoking reinstatement will be modeled, as&#xD;
      participant will have opportunity to smoke. A variety of behavioral, subjective,&#xD;
      physiological, and performance measures will be assessed throughout the study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2006</start_date>
  <completion_date type="Actual">May 2009</completion_date>
  <primary_completion_date type="Actual">May 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Use of cigarettes</measure>
    <time_frame>Day 15</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Tobacco Use Disorder</condition>
  <arm_group>
    <arm_group_label>Intervention 1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Each participant receives three consecutive interventions.&#xD;
Placebo&#xD;
Bupropion&#xD;
Memantine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intervention 2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Bupropion&#xD;
Memantine&#xD;
Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intervention 3</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Memantine&#xD;
Placebo&#xD;
Bupropion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Memantine</intervention_name>
    <arm_group_label>Intervention 1</arm_group_label>
    <arm_group_label>Intervention 2</arm_group_label>
    <arm_group_label>Intervention 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  DSM-IV diagnosis of nicotine dependence with psychological dependence&#xD;
&#xD;
          -  Smokes at least 15 cigarettes per day for the three months prior to enrollment&#xD;
&#xD;
          -  Currently not seeking treatment for nicotine dependence&#xD;
&#xD;
          -  Medically healthy on the basis of physical examination and medical history, vital&#xD;
             signs, EKG, and laboratory tests&#xD;
&#xD;
          -  Females must use an effective method of contraception for the duration of the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  DSM-IV diagnosis of abuse or dependence on alcohol or drugs other than nicotine&#xD;
&#xD;
          -  Current Axis I diagnosis or current treatment with psychotropic medications within the&#xD;
             three months prior to enrollment&#xD;
&#xD;
          -  History of schizophrenia or other psychotic disorders, bipolar disorder, or anxiety&#xD;
             disorders&#xD;
&#xD;
          -  Currently seeking treatment for nicotine disorders&#xD;
&#xD;
          -  On parole or probation&#xD;
&#xD;
          -  History of seizures or head trauma with loss of consciousness, brain contusion, or&#xD;
             fracture&#xD;
&#xD;
          -  History of significant recent violent behavior&#xD;
&#xD;
          -  Blood pressure greater than 150/90&#xD;
&#xD;
          -  History of eating disorders&#xD;
&#xD;
          -  History of allergic reaction to any of the study medications&#xD;
&#xD;
          -  Pregnant&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adam Bisaga, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>New York State Psychiatric Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>New York State Psychiatric Institute</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <study_first_submitted>August 25, 2005</study_first_submitted>
  <study_first_submitted_qc>August 25, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 29, 2005</study_first_posted>
  <last_update_submitted>May 17, 2018</last_update_submitted>
  <last_update_submitted_qc>May 17, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 21, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>New York State Psychiatric Institute</investigator_affiliation>
    <investigator_full_name>Adam Bisaga</investigator_full_name>
    <investigator_title>Research Psychiatrist</investigator_title>
  </responsible_party>
  <keyword>tobacco use</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tobacco Use Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Memantine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

